According to a study, published in The Lancet, the therapy is safe for women and babies, but fails to reduce the chances of women giving birth prematurely.
The progesterone hormone is used as part of premature birth therapy.
Following the published results, researchers are now calling for the therapy to be reviewed and more effort should be made to find alternative interventions.
In conclusion to the research: “For those clinicians and women who wish still to use progesterone for preterm birth prophylaxis, our data provide reassurance that it appears safe, at least until 2 years of age of the child.”
Findings were found based on a trial involving 1,200 women between February 2009 and April 2013, across 64 UK hospitals, and led by the Tommy’s Centre for Maternal and Fetal Health at the University of Edinburgh.
The study focused on women who were considered to have a greater risk of having a premature birth, either through giving birth early previously or who have suffered a miscarriage during the late stages of pregnancy.
Sourced from The Independent, Director of Tommy’s Centre for Maternal and Fetal health, Jane Norman said: “Babies born too early have a much greater risk of short-term and long-term health problems. We need to find new strategies that help mums carry their babies to term.”
Keep up to date with the latest news from MIDIRS by signing up to our e-newsletter. Sign-up